18F-Fluorodeoxyglucose PET/CT-Guided Palliative Radiotherapy Provides Durable Responses to Over a Dozen Sites of Disease in Relapsed Myeloid Sarcoma

ABSTRACTMyeloid sarcoma (MS) is a rare entity, and FDG PET/CT is a useful tool for staging at diagnosis and response assessment. We present a case of a 72-year-old woman diagnosed with multifocal extramedullary MS, using FDG PET/CT to guide palliative radiotherapy to 13 sites of disease over 2 separ...

Full description

Saved in:
Bibliographic Details
Published in:Clinical nuclear medicine 2020-11, Vol.45 (11), p.886-887
Main Authors: Shuttleworth, Charles, Wegner, Eva A., Thompson, Stephen R., Kidson-Gerber, Giselle
Format: Article
Language:English
Subjects:
Aged
Female
Fluorodeoxyglucose F18
Humans
Neoplasm Staging
Palliative Care
Positron Emission Tomography Computed Tomography
Radiotherapy, Image-Guided
Recurrence
Sarcoma, Myeloid - diagnostic imaging
Sarcoma, Myeloid - pathology
Sarcoma, Myeloid - radiotherapy
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACTMyeloid sarcoma (MS) is a rare entity, and FDG PET/CT is a useful tool for staging at diagnosis and response assessment. We present a case of a 72-year-old woman diagnosed with multifocal extramedullary MS, using FDG PET/CT to guide palliative radiotherapy to 13 sites of disease over 2 separate relapses with complete and durable local responses and minimal toxicity. This case represents the largest reported burden of disease in MS successfully treated with FDG PET/CT-guided radiotherapy.
ISSN:0363-9762
1536-0229
DOI:10.1097/RLU.0000000000003238